Turning complex chemistry challenges into discovery success.
With deep expertise in medicinal chemistry and synthetic chemistry, Jubilant Biosys partners with biotech and pharmaceutical innovators to advance programs from concept to candidate.
#JubilantBiosys#MedicinalChemistry
Scientific depth. Integrated expertise. Faster discovery.
From target validation to lead optimization, Jubilant combines the power of biology and chemistry with multidisciplinary capabilities across assay biology, protein sciences, DMPK, pharmacology, and computational chemistry.
Meet the Jubilant Biosys team and discover how our integrated drug discovery and development capabilities help biotech and pharmaceutical companies accelerate innovation and make informed development decisions with confidence.
๐ October 29-30, 2026
๐ Meliรก Madrid Barajas, Spain
Valuable discussions, new connections, and exciting science at World ADC San Diego 2026.
Our team was pleased to be part of this premier gathering of the ADC community, engaging with industry experts and innovators focused on advancing the next generation of targeted therapies.
Beyond the booth, the banners, and the meeting rooms, CPHI Milan 2026 was about conversations.
Conversations about scientific challenges, accelerating development timelines. Conversations about creating stronger partnerships across the pharma and biotech ecosystem.
A big thank you to everyone who has stopped by our booth and connected with the team. It's been a pleasure exchanging ideas, exploring opportunities, and discussing how our integrated capabilities can support your journey from discovery and development through commercialization.
Jubilant Biosys is excited to participate in the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) 2026 in Denver, Colorado.
Connect with Manas Verma, Director, Business Development
๐ October 11-14, 2026
๐ Denver, CO
Jubilant Biosys is featured on https://t.co/XJG78uWpI5, highlighting how integrated infrastructure and multidisciplinary scientific expertise support smarter, faster decision-making across the drug discovery continuum.
Read the full blog - https://t.co/CGfJDCFK6A
This October, our leadership team will be in Milan to lead conversations across the pharmaceutical value chain.
Shantanu Jha, Acting CEO, Jubilant Biosys & Group CHRO, Jubilant Bhartia, will join our team at CPHI Milan 2026
๐ 6โ8 October 2026
๐Fiera Milano, Italy
๐นBooth 6K57
Responsible Use of Generative AI in Medicinal Chemistry.
Explore our latest article by Dr. Prasant Deb, Senior Vice President & Site Head, Noida & Greater Noida, on the responsible use of Generative AI in Medicinal Chemistry.
Read here: https://t.co/ld7X34Fcdw
We are pleased to participate in ChemOutsourcing 2026, where industry leaders will come together to discuss the future of pharma outsourcing and innovation.
Presenter - TJ Sigler, Sr. VP - Business Development
Topic - CDMO Outsourcing in India: Breaking Through the Noise
A new green space was inaugurated at our CDMO and API manufacturing facility in Nanjangud by Mr. Shantanu Jha (Acting CEO, Jubilant Biosys & Group CHRO).
At Jubilant Biosys, our integrated API and CDMO capabilities help accelerate development timelines through efficient process design, seamless technology transfer, and scalable manufacturing solutions. We support partners in bringing high-quality APIs to market with confidence.
A celebration of culture, connection and the people behind our science.
As India marked its 80th Independence Day, colleagues across Jubilant Biosys came together to honour the spirit of freedom, unity and responsibility.
Here are a few glimpses from the celebrations.
Jubilant Biosys offers dedicated FTE teams that can be deployed around your program, with integrated access to CADD, DMPK and biology.
30โ50 compounds per DMTA cycle | 1โ2-week turnaround
See how the model could support your pipeline.
Jubilant Biosys provides dedicated FTE teams tailored to your program, with seamless access to CADD, biology, and DMPK expertise.
โ 30-50 compounds per DMTA cycle
โ 1-2 week turnaround times
โ Flexible team scaling based on project needs
At Jubilant Biosys, our integrated CRDMO platform bridges the gap between AI-driven insights and real-world execution, helping innovators move from molecule design to development-ready candidates with confidence.
Venugopala Reddy Pagadala, Vice President & CFO, shares - disciplined financial management and unwavering compliance have played a pivotal role in strengthening stakeholder confidence and positioning the finance function as a key driver of business performance.
AI can design molecules. Science brings them to life.
At Jubilant Biosys, we combine integrated Chemistry, Biology, and DMPK capabilities with scalable development solutions to help innovators advance AI-designed molecules with confidence